PL190098B1 - Mikrocząsteczkowa postać chlorowodorku 1-[2-(2-naftylo)etylo]-4-(3-trifluorometylofenylo)-1,2,3,6-tetrahydropirydyny oraz kompozycja zawierająca tę postać - Google Patents

Mikrocząsteczkowa postać chlorowodorku 1-[2-(2-naftylo)etylo]-4-(3-trifluorometylofenylo)-1,2,3,6-tetrahydropirydyny oraz kompozycja zawierająca tę postać

Info

Publication number
PL190098B1
PL190098B1 PL97334276A PL33427697A PL190098B1 PL 190098 B1 PL190098 B1 PL 190098B1 PL 97334276 A PL97334276 A PL 97334276A PL 33427697 A PL33427697 A PL 33427697A PL 190098 B1 PL190098 B1 PL 190098B1
Authority
PL
Poland
Prior art keywords
microparticles
micrometers
active ingredient
diameter
less
Prior art date
Application number
PL97334276A
Other languages
English (en)
Polish (pl)
Other versions
PL334276A1 (en
Inventor
Antoine Caron
Jean-Pierre Chambon
Olivier Monnier
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PL334276A1 publication Critical patent/PL334276A1/xx
Publication of PL190098B1 publication Critical patent/PL190098B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
PL97334276A 1996-12-23 1997-12-23 Mikrocząsteczkowa postać chlorowodorku 1-[2-(2-naftylo)etylo]-4-(3-trifluorometylofenylo)-1,2,3,6-tetrahydropirydyny oraz kompozycja zawierająca tę postać PL190098B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9615905A FR2757510B1 (fr) 1996-12-23 1996-12-23 Forme microparticulaire d'un derive de tetrahydropyridine
PCT/FR1997/002394 WO1998028272A1 (fr) 1996-12-23 1997-12-23 Forme microparticulaire d'un derive de tetrahydropyridine

Publications (2)

Publication Number Publication Date
PL334276A1 PL334276A1 (en) 2000-02-14
PL190098B1 true PL190098B1 (pl) 2005-10-31

Family

ID=9499044

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97334276A PL190098B1 (pl) 1996-12-23 1997-12-23 Mikrocząsteczkowa postać chlorowodorku 1-[2-(2-naftylo)etylo]-4-(3-trifluorometylofenylo)-1,2,3,6-tetrahydropirydyny oraz kompozycja zawierająca tę postać

Country Status (37)

Country Link
US (4) US20020028247A1 (enExample)
EP (1) EP0950051B1 (enExample)
JP (2) JP4422214B2 (enExample)
KR (1) KR100455797B1 (enExample)
CN (1) CN1088698C (enExample)
AR (1) AR009673A1 (enExample)
AT (1) ATE250032T1 (enExample)
AU (1) AU730302B2 (enExample)
BR (1) BR9714177A (enExample)
CA (1) CA2275593C (enExample)
CO (1) CO4920213A1 (enExample)
CZ (1) CZ294272B6 (enExample)
DE (1) DE69724999T2 (enExample)
DK (1) DK0950051T3 (enExample)
DZ (1) DZ2386A1 (enExample)
EE (1) EE04112B1 (enExample)
EG (1) EG24749A (enExample)
ES (1) ES2207758T3 (enExample)
FR (1) FR2757510B1 (enExample)
HU (1) HU224348B1 (enExample)
IL (1) IL129937A (enExample)
IN (1) IN186977B (enExample)
IS (1) IS2064B (enExample)
MY (1) MY126298A (enExample)
NO (1) NO311569B1 (enExample)
NZ (1) NZ336129A (enExample)
PL (1) PL190098B1 (enExample)
PT (1) PT950051E (enExample)
RU (1) RU2193031C2 (enExample)
SI (1) SI0950051T1 (enExample)
SK (1) SK283917B6 (enExample)
TR (1) TR199901362T2 (enExample)
TW (1) TW534820B (enExample)
UA (1) UA66776C2 (enExample)
WO (1) WO1998028272A1 (enExample)
YU (1) YU49427B (enExample)
ZA (1) ZA9711579B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2739852T3 (es) * 2001-07-06 2020-02-04 Veloxis Pharmaceuticals As Aglomeración controlada
BE1015641A4 (fr) * 2003-05-26 2005-07-05 Mariani Jean Paul Micronisation 70.
RU2472490C1 (ru) * 2011-08-05 2013-01-20 Открытое акционерное общество "Биосинтез" Средство для лечения кожных гнойных инфекций, составы и способы получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562883A (en) * 1896-06-30 Thill-coupling
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
ES2127835T3 (es) * 1992-10-26 1999-05-01 Sanol Arznei Schwarz Gmbh Procedimiento para la preparacion de microcapsulas.
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US6489334B2 (en) * 1996-12-23 2002-12-03 Sanofi-Synthelabo Method for the crystallization of a tetrahydropyridin derivative and resulting crystalline forms
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
US20020147216A1 (en) * 2000-01-31 2002-10-10 Yuhong Zhou Mucin synthesis inhibitors

Also Published As

Publication number Publication date
DE69724999T2 (de) 2004-07-22
FR2757510B1 (fr) 2000-01-07
PT950051E (pt) 2004-02-27
US20100021541A1 (en) 2010-01-28
DE69724999D1 (de) 2003-10-23
TR199901362T2 (xx) 1999-09-21
EP0950051A1 (fr) 1999-10-20
CZ229199A3 (cs) 1999-09-15
IS5077A (is) 1999-06-10
NO993077L (no) 1999-06-22
CN1241179A (zh) 2000-01-12
IL129937A0 (en) 2000-02-29
HUP0001181A2 (hu) 2000-11-28
ATE250032T1 (de) 2003-10-15
ES2207758T3 (es) 2004-06-01
AU730302B2 (en) 2001-03-01
UA66776C2 (uk) 2004-06-15
PL334276A1 (en) 2000-02-14
EG24749A (en) 2010-07-20
NO311569B1 (no) 2001-12-10
TW534820B (en) 2003-06-01
KR100455797B1 (ko) 2004-11-06
SK283917B6 (sk) 2004-05-04
CZ294272B6 (cs) 2004-11-10
US20020028247A1 (en) 2002-03-07
SI0950051T1 (en) 2004-02-29
CN1088698C (zh) 2002-08-07
CA2275593C (en) 2005-12-20
AR009673A1 (es) 2000-04-26
IN186977B (enExample) 2001-12-22
EE04112B1 (et) 2003-08-15
US20020192292A1 (en) 2002-12-19
HUP0001181A3 (en) 2003-03-28
YU28899A (sh) 2000-03-21
BR9714177A (pt) 2000-02-29
RU2193031C2 (ru) 2002-11-20
NZ336129A (en) 2000-11-24
IS2064B (is) 2005-11-15
YU49427B (sh) 2006-01-16
KR20000069503A (ko) 2000-11-25
ZA9711579B (en) 1998-06-25
EE9900263A (et) 2000-02-15
AU5668598A (en) 1998-07-17
US20080255365A1 (en) 2008-10-16
HU224348B1 (hu) 2005-08-29
CO4920213A1 (es) 2000-05-29
JP2009280581A (ja) 2009-12-03
FR2757510A1 (fr) 1998-06-26
NO993077D0 (no) 1999-06-22
IL129937A (en) 2002-09-12
DZ2386A1 (fr) 2002-12-28
HK1024000A1 (en) 2000-09-29
JP4422214B2 (ja) 2010-02-24
SK82999A3 (en) 1999-12-10
DK0950051T3 (da) 2004-01-26
WO1998028272A1 (fr) 1998-07-02
CA2275593A1 (en) 1998-07-02
MY126298A (en) 2006-09-29
EP0950051B1 (fr) 2003-09-17
JP2001507013A (ja) 2001-05-29

Similar Documents

Publication Publication Date Title
JP3541042B2 (ja) 置換３，５―ジフェニル―１，２，４―トリアゾールおよび製薬的金属キレート化剤としてのその使用
US4309430A (en) Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same
US6143775A (en) Process for preparing pharmaceutical composition containing a heterocyclic amide
KR100418174B1 (ko) 인다졸카르복스아미드
JPH08504798A (ja) 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
CN87100563A (zh) 含n-杂环基-4-哌啶胺类的抗组胺组合物
HU209576B (en) Process for producing pyrimidine derivatives and pharmaceutical preparations containing them
PL183867B1 (pl) Nowe indazolokarboksyamidy, sposób ich wytwarzania i środek farmaceutyczny
SK2842003A3 (en) A solid unit dosage form comprising citalopram, crystals of a pharmaceutical acceptable salt of citalopram and method for the manufacture of said crystals
US20100021541A1 (en) Microparticulate form of a Tetrahydropyridine derivative
HK175896A (en) Medicament for the treatment of cardiac insufficiency
MXPA99005621A (en) Micro-particulate form of a tetrahydropyridin derivative
JP4499188B2 (ja) テトラヒドロピリジン誘導体を結晶化する方法及び得られる結晶形
HRP970701A2 (en) Micro-particulate form of a tetrahydropyridin derivative
US4614743A (en) Methods of treating pain and inflammation with 4,7-dimethyl-2-(4-pyridinyl)-1,2,4,-triazolo[1,5-a]pyrimidin-5(4H)-one or the pharmaceutically acceptable salts or solvates thereof
JPS58109489A (ja) イミダゾベンゾジアゼピン化合物、該化合物を含有する医薬製剤及び該化合物の製造方法
SA98180973B1 (ar) شكل جسيمي متناهي في الصغر من مشتق رباعي هيدرو بيريدين tetrahydropyridine
HK1024000B (en) Micro-particulate form of a tetrahydropyridin derivative
KR100554704B1 (ko) 1-메틸-5-ｐ-톨루오일피롤-2-아세트아미도아세트산 과이아실에스테르(ＭＥＤ 15) 화합물의 신규 결정동질이상 형태
EP0623616A1 (en) Heterocyclic compounds and process for the preparation thereof
HK1019003A1 (en) Use of 2-amino-6-a-propylamino-4,5,6,7-tetrahydrobenzothiazole(pramipexol) as an anti-depressant drug
HK1019003B (en) Use of 2-amino-6-a-propylamino-4,5,6,7-tetrahydrobenzothiazole(pramipexol) as an anti-depressant drug

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20121223